Faricimab clinical trials, in English

This randomly assigned controlled trial will measure the effect of intravitreal faricimab or fluocinolone acetonide (FAc) intravitreal implant compared with observation on long-term visual acuity following treatment of choroidal melanoma with iodine-125 plaque brachytherapy.

NCT05844982 · Official ClinicalTrials.gov record · Jaeb Center for Health Research

Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal antibody treatments ranibizumab \[1\] and aflibercept \[2\] in the 2010s.

NCT06271330 · Official ClinicalTrials.gov record · Nantes University Hospital

The goal of this clinical trial is to assess the how well it works, safety and durability of faricimab in caucasian patients with polypoidal choroidal vasculopathy (PCV). The main question it aims to answer is: To measure the how well it works of intravitreal (IVT) injections of faricimab 6 milligrams (mg) on Best Corrected Visual Acuity (BCVA) outcomes in caucasian patients with symptomatic macular PCV.

NCT06709339 · Official ClinicalTrials.gov record · Association for Innovation and Biomedical Research on Light and Image

We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.

NCT06742307 · Official ClinicalTrials.gov record · Hospital Authority, Hong Kong

This randomly assigned trial will compare treatment strategies for proliferative diabetic retinopathy (PDR). Participants will receive either combination a of faricimab + PRP or vitrectomy + endolaser.

NCT06790784 · Official ClinicalTrials.gov record · Jaeb Center for Health Research

This is a prospective, randomly assigned study that compares 8-week and 12-week follow-up intervals after the 4 monthly injections in the loading phase. Patients with active CNV confirmed on optical coherence tomography (OCT) and OCT angiography (OCTA) will be randomly assigned into two groups and followed for 44 to 56 weeks.

NCT06875245 · Official ClinicalTrials.gov record · Faculty Hospital Kralovske Vinohrady

This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration.

NCT06929507 · Official ClinicalTrials.gov record · University Hospital, Alexandroupolis

Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40% have a suboptimal response.

NCT07249216 · Official ClinicalTrials.gov record · Singapore National Eye Centre

If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected.

NCT07367282 · Official ClinicalTrials.gov record · Junyeop Lee

Whose aim is to: Determine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16. This study is intended to be performed in the ophthalmology departments or ophthalmology clinics of the participating sites, located in Spain.

NCT07403825 · Official ClinicalTrials.gov record · Biobizkaia Health Research Institute

This study wants to measure the safety, tolerability, Pharmacodynamics (PD), and Pharmacokinetics (PK) of multiple doses of RO7823653 in participants with DME, administered by intravitreal (IVT) injection as this drug alone and co-administered with faricimab.

NCT07425522 · Official ClinicalTrials.gov record · Genentech, Inc.

To measure the how well it works of a personalized treat-and-extend regimen of faricimab for treatment-who have not tried this kind of treatment before polypoidal choroidal vasculopathy

NCT07461441 · Official ClinicalTrials.gov record · Yeungnam University College of Medicine

The goal of this clinical trial is to see if treatment with faricimab or biosimilar ranibizumab leads to different early imaging changes in adults with diabetic retinopathy requiring anti-VEGF treatment and to identify OCT and OCTA biomarkers predictive of differential early treatment response between the two therapies. The main questions it aims to answer are: Which OCT and OCT angiography biomarkers predict early treatment response?

NCT07520045 · Official ClinicalTrials.gov record · Osijek University Hospital

This study will measure the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)

NCT07695298 · Official ClinicalTrials.gov record · Cincinnati Eye Institute, Southwest Ohio